Log in to search using one of your social media accounts:

 

Childhood CAP: Would Adding Dexamethasone Hasten Recovery? Childhood CAP: Would Adding Dexamethasone Hasten Recovery?
Could steroids, in addition to antibiotics, bring about faster recovery in children with CAP and pleural effusion?Medscape Pediatrics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 18, 2017 Category: Consumer Health News Tags: Pediatrics Viewpoint Source Type: news

Lucky Mart Inc. Issues Voluntary Nationwide Recall Of Piyanping Anti-Itch Lotion Due to Incorrect Active Ingredient
Lucky Mart Inc. is voluntarily recalling lots C14005, C16001 and C16002 of Piyanping Anti-Itch Lotion to the consumer level. The product was manufactured using the active pharmaceutical ingredient dexamethasone rather than hydrocortisone. Dexamethasone is not listed as an ingredient in the labeling. (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 30, 2017 Category: Food Science Source Type: news

Long-Term Analysis Of Phase 3 Head-To-Head Study Confirms KYPROLIS ® (Carfilzomib) Regimen Extends Overall Survival In Patients With Relapsed Multiple Myeloma
ENDEAVOR Study Long-Term Data Shows KYPROLIS and Dexamethasone Reduced the Risk of Death by 24 Percent Versus Velcade® (Bortezomib) and Dexamethasone Patients Treated With the KYPROLIS-Based Regimen Survived 9.0 Months Longer Than Patients Receiving Velcade and Dexamethasone Long-Term Follow-Up Demonstrated Consistent Safety Profile THOUSAND OAKS, Calif., Aug. 30, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive results from a post-hoc analysis requested by the U.S. Food and Drug Administration (FDA) of the Phase 3 head-to-head ENDEAVOR trial, which followed patients for at least three y...
Source: Amgen News Release - August 30, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Accepts Amgen's Filing Of A Supplemental New Drug Application To Add Overall Survival Results To KYPROLIS ® (Carfilzomib) Label
FDA Sets PDUFA Target Action Date of April 30, 2018 THOUSAND OAKS, Calif., Aug. 30, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) based on the overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial demonstrating that KYPROLIS® (carfilzomib) and dexamethasone (Kd) reduced the risk of death by 21 percent and increased OS by 7.6 months versus Velcade® (bortezomib) and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (median OS 47.6 mon...
Source: Amgen News Release - August 30, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Overall Survival Analysis From KYPROLIS ® (carfilzomib) Phase 3 Endeavor Trial Published In The Lancet Oncology
KYPROLIS and Dexamethasone Reduced the Risk of Death by 21 Percent Compared to Velcade® (bortezomib) and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients KYPROLIS is the First and Only Multiple Myeloma Therapy Proven to Extend Overall Survival in a Head-to-Head Comparison With a Current Standard of Care in the Relapsed Setting THOUSAND OAKS, Calif., Aug. 23, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that results from an overall survival (OS) analysis of the Phase 3 head-to-head ENDEAVOR trial were published online first in The Lancet Oncology. Data showed that KYPROLIS® (...
Source: Amgen News Release - August 23, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

At What Height Do You Consider Preventative Treatment for Acute Mountain Sickness?
Discussion Acute mountain sickness (AMS) is a well-known problem for some people who travel to high altitude, especially altitudes> 2500 m (~8200 feet). Symptoms include headache, nausea or emesis, shortness of breath, dizziness, fatigue, difficulty sleeping and poor appetite. The incidence in adults ranges from 25% at 2975 m to up to 75% at 5896 m. The incidence in children is less clear but it appears that children are more susceptible at 45% for 16-19 year olds for similar altitudes. Risk factors are numerous including age, gender, obesity, ascent rate, altitude for sleeping, previous exposure to high altitude, previ...
Source: PediatricEducation.org - August 21, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Reduced Retreatment Dose Feasible in Relapsed, Refractory Multiple Myeloma
Prolonged use of bortezomib after treatment with combined bortezomib plus dexamethasone did not result in any significant benefit for patients with relapsed/refractory multiple myeloma compared with bortezomib plus dexamethasone alone, but this less dose-intensive approach could be a feasible option for patients who cannot tolerate the standard regimen. (Source: CancerNetwork)
Source: CancerNetwork - August 19, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

SMC approves Amgen ’s carfilzomib for multiple myeloma treatment
The Scottish Medicines Consortium (SMC) has approved the routine use of Amgen ’s carfilzomib (Kyprolis), in combination with dexamethasone, for the treatment of multiple myeloma across National Health Service (NHS) Scotland. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 8, 2017 Category: Pharmaceuticals Source Type: news

Droperidol + OND and DEX in Children for Postop Vomiting Droperidol + OND and DEX in Children for Postop Vomiting
The combination of dexamethasone, ondansetron, and droperidol has been shown to be effective in preventing postoperative nausea and vomiting in adults. Is it safe and effective for children?British Journal of Anaesthesia (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 3, 2017 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news

Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS ® (Carfilzomib) Label
Data Showed KYPROLIS and Dexamethasone Reduced the Risk of Death by 21 Percent and Increased Overall Survival by 7.6 Months Compared to Velcade® (Bortezomib) and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients THOUSAND OAKS, Calif., July 14, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and a variation to the marketing application to the European Medicines Agency (EMA) to include overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial in the product information fo...
Source: Amgen News Release - July 14, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen ’s multiple myeloma drug shows positive outcome in Phase III trial
Amgen has reported a positive outcome from the Phase III clinical trial (ASPIRE) of Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone (KRd) to treat relapsed multiple myeloma. (Source: Drug Development Technology)
Source: Drug Development Technology - July 13, 2017 Category: Pharmaceuticals Source Type: news

Second Phase 3 Study Shows KYPROLIS ® (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma
KYPROLIS, Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Patients Treated With the KYPROLIS-Based Regimen Survived 7.9 Months Longer Than Patients on Lenalidomide and Dexamethasone KYPROLIS-Based Regimens Are the First and Only to Demonstrate Improved Overall Survival Versus Today's Standards of Care in Two Phase 3 Studies in Relapsed Multiple Myeloma THOUSAND OAKS, Calif., July 12, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive results from the final analysis of the Phase 3 ASPIRE trial. The study met the key secondary endpoint ...
Source: Amgen News Release - July 12, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Rapid, Durable Responses in Advanced Myeloma With Daratumumab Combo
Treatment with the combination of daratumumab plus pomalidomide/dexamethasone resulted in rapid, deep, and sustained responses with no new safety signals in patients with heavily treated multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - July 12, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Ocular seeks to extend regulatory timeline for Dextenza due to manufacturing concerns
Ocular Therapeutix (NSDQ:OCUL) said today that it submitted details of a manufacturing equipment change as an amendment to the new drug application resubmission for Dextenza, the company’s dexamethasone insert that is currently under review by the FDA. The FDA is slated to make a decision about the product’s regulatory approval by July 19. But the company recently revealed that the FDA issued a Form 483 to Ocular following a pre-approval inspection of a manufacturing facility, which detailed a number of issues relating to the manufacture of Dextenza. Get the full story at our sister site, Dr...
Source: Mass Device - July 11, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Legal News Optical/Ophthalmic Pharmaceuticals Regulatory/Compliance Wall Street Beat oculartherapeutix Source Type: news

NK-1RA-Based Triple Regimens in Preventing CINV NK-1RA-Based Triple Regimens in Preventing CINV
Do efficacy and toxicity vary among different NK-1RA-based triple regimens for prevention of CINV? What is the optimal dose of dexamethasone?Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 22, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Amgen To Present New Data At 22nd Congress of the European Hematology Association
Oral Presentation of Phase 3 Data Shows KYPROLIS® (Carfilzomib) and Dexamethasone Improved Median Overall Survival by 7.6 Months Compared to Velcade® (Bortezomib) and Dexamethasone in Relapsed Multiple Myeloma New Subset Analysis Demonstrates BLINCYTO® (Blinatumomab) More Than Doubled Median Overall Survival Versus Standard of Care Chemotherapy in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Salvage Oral Presentation of New Data From Head-to-Head Phase 3 Study of XGEVA® (Denosumab) Versus Zoledronic Acid in Time to First On-Study Skeletal...
Source: Amgen News Release - June 21, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Hexadrol (Dexamethasone Sodium Phosphate Injection, USP) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 21, 2017 Category: Drugs & Pharmacology Source Type: news

Daratumumab/Pomalidomide Combo Approved for Relapsed, Refractory Myeloma
The FDA has approved daratumumab in combination with pomalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - June 21, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Triplet Combo Active in Lenalidomide/Refractory Multiple Myeloma
Combining bendamustine, pomalidomide, and dexamethasone achieved a promising overall response rate in patients with heavily pretreated lenalidomide refractory multiple myeloma, according to the results of a phase I/II trial. (Source: CancerNetwork)
Source: CancerNetwork - June 20, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Triplet Combo Active in Lenalidomide-Refractory Multiple Myeloma
Combining bendamustine, pomalidomide, and dexamethasone achieved a promising overall response rate in patients with heavily pretreated lenalidomide refractory multiple myeloma, according to the results of a phase I/II trial. (Source: CancerNetwork)
Source: CancerNetwork - June 20, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

DARZALEX ® (daratumumab) Approved by the U.S. FDA in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Who Have Received At Least Two Prior Therapies
DARZALEX combination therapy offers new option for patients previously treated with two commonly used treatments (lenalidomide and a proteasome inhibitor) (Source: Johnson and Johnson)
Source: Johnson and Johnson - June 17, 2017 Category: Pharmaceuticals Source Type: news

Genmab Announces U.S. FDA Approval of Darzalex (daratumumab) in Combination with Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Copenhagen, Denmark; June 16, 2017 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today the U.S. Food and Drug Administration (FDA) has approved the use of Darzalex (daratumumab) in combination with pomalidomide and dexamethasone for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 16, 2017 Category: Drugs & Pharmacology Source Type: news

Dexamethasone facilitates fear extinction and safety discrimination in PTSD: a placebo-controlled, double-blind study - Michopoulos V, Norrholm SD, Stevens JS, Glover EM, Rothbaum BO, Gillespie CF, Schwartz AC, Ressler KJ, Jovanovic T.
Psychophysiological hallmarks of posttraumatic stress disorder (PTSD) include exaggerated fear responses, impaired inhibition and extinction of conditioned fear, and decreased discrimination between safety and fear cues. This increased fear load associated... (Source: SafetyLit)
Source: SafetyLit - June 14, 2017 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

NICE recommends Amgen's carfilzomib with dexamethasone for RMM treatment
The National Institute for Health and Care Excellence (NICE) in the UK has recommended US-based biopharmaceutical company Amgen's Kyprolis (Carfilzomib) in combination with dexamethasone as an option for treating adults with relapsed multiple myeloma … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 13, 2017 Category: Pharmaceuticals Source Type: news

New study highlights patient concerns about glucocorticoid side effects
This study has shown that weight gain, insomnia and moon face were the top three most important side effects to patients taking glucocorticoids. Despite this, they are not widely studied, with many unanswered questions. "Research should be informed by patients, and targeted to provide patients with better information about these side effects of high importance." Arthritis Research UK's view Devi Rani Sagar, research liaison manager at Arthritis Research UK, said:"We believe that people with arthritis should get the recognition and support they deserve, and that's why we invest in research to find the...
Source: Arthritis Research UK - June 13, 2017 Category: Rheumatology Source Type: news

Significant Toxicity, Infection Risk Associated With Elo-RVD in Myeloma
In patients with newly diagnosed multiple myeloma, elotuzumab plus bortezomib, lenalidomide, and dexamethasone was associated with significant toxicity and infections. (Source: CancerNetwork)
Source: CancerNetwork - June 12, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Multiple Myeloma News Source Type: news

Isatuximab Combination Safe, Active for Relapsed, Refractory Myeloma
The combination of the anti-CD38 monoclonal antibody isatuximab with pomalidomide/dexamethasone had an acceptable and manageable safety profile in patients with relapsed or refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - June 9, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Multiple Myeloma Hematologic Malignancies News Source Type: news

Can a Preop Steroid Injection Reduce Post-op Vomiting? Can a Preop Steroid Injection Reduce Post-op Vomiting?
Dr Lowenfels comments on a study comparing dexamethasone versus standard therapy for reducing the frequency of postop vomiting after surgery, published in BMJ.Medscape General Surgery (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 8, 2017 Category: Consumer Health News Tags: General Surgery Viewpoint Source Type: news

Janssen reports positive results from two Phase III combination trials of Darzalex
Janssen Research& Development has reported positive results from the updated Phase III CASTOR and POLLUX clinical trials of Darzalex (daratumumab) combined with bortezomib and dexamethasone or lenalidomide and dexamethasone to treat patients with mu … (Source: Drug Development Technology)
Source: Drug Development Technology - June 5, 2017 Category: Pharmaceuticals Source Type: news

Pembrolizumab Combo Active in Relapsed/Refractory Myeloma
Combination treatment with pembrolizumab, pomalidomide, and low-dose dexamethasone resulted in durable responses in patients with relapsed or refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - May 16, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

tobramycin and dexamethasone, Tobradex, Tobradex ST
Title: tobramycin and dexamethasone, Tobradex, Tobradex STCategory: MedicationsCreated: 7/23/1998 12:00:00 AMLast Editorial Review: 5/12/2017 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - May 12, 2017 Category: Opthalmology Source Type: news

Outcomes and Impact of Age on Therapy for Multiple Myeloma Outcomes and Impact of Age on Therapy for Multiple Myeloma
Is lenalidomide with low-dose dexamethasone effective for stem-cell transplantation-ineligible patients of any age with newly diagnosed MM?Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 12, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Dexamethasone for Postop Nausea and Vomiting in GI Surgery Dexamethasone for Postop Nausea and Vomiting in GI Surgery
Can a dose of I.V. dexamethasone at induction of anesthesia significantly reduce the incidence of postoperative nausea and vomiting in patients undergoing bowel surgery?The BMJ (formerly known as the British Medical Journal) (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 12, 2017 Category: Consumer Health News Tags: General Surgery Journal Article Source Type: news

Local Steroid Injection Shuts Down Leg Inflammation after PAD Tx
(MedPage Today) -- Make way for dexamethasone, other drugs targeted to the adventitia (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 11, 2017 Category: Cardiology Source Type: news

Ocular ’ s Dextenza meets primary endpoints in Phase III trial
Shares in Ocular Therapeutix (NSDQ:OCUL) rose more than 5% today after the company said its Dextenza post-surgical ocular pain relief implant met primary endpoints in the company’s most recent Phase III trial. The hydrogel plug, inserted into a patient’s tear duct, is designed to deliver a sustained dose of dexamethasone over 4 weeks following ophthalmic surgery. The FDA is slated to make a decision whether or not to approve Dextenza for the treatment of ocular pain after ophthalmic surgery by July 19, 2017. Get the full story at our sister site, Drug Delivery Business News. The post Ocular’s De...
Source: Mass Device - May 8, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Wall Street Beat Ocular Therapeutix Source Type: news

Dexamethasone at Anesthesia Induction to Prevent Postop Nausea Dexamethasone at Anesthesia Induction to Prevent Postop Nausea
A dose of dexamethasone at anesthesia induction can help ward off postoperative nausea and vomiting (PONV) in non-diabetic patients undergoing elective bowel surgery, new findings show.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - May 3, 2017 Category: Surgery Tags: General Surgery News Source Type: news

Genmab to investigate daratumumab in Phase III combination trial for multiple myeloma
Danish biotechnology firm Genmab is set to investigate the combination of daratumumab with pomalidomide and dexamethasone in its Phase III clinical trial to treat patients with relapsed and refractory multiple myeloma. (Source: Drug Development Technology)
Source: Drug Development Technology - May 1, 2017 Category: Pharmaceuticals Source Type: news

Effectiveness of steroid medication for sore throat
In patients with a sore throat that didn't require immediate antibiotics, dexamethasone didn't increase the likelihood of complete symptom resolution after 24 hours, but more patients reported feeling completely better after 48 hours, according to a study published inJAMA.Science Daily  (Source: Society for Endocrinology)
Source: Society for Endocrinology - April 21, 2017 Category: Endocrinology Source Type: news

Dexamethasone for Acute Sore Throat? (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM Dexamethasone may offer some relief for acute sore throat, a JAMA study finds.Nearly 600 U.K. adults presenting to primary care with acute sore … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 18, 2017 Category: Primary Care Source Type: news

Study examines effectiveness of steroid medication for sore throat
In patients with a sore throat that didn't require immediate antibiotics, a single capsule of the corticosteroid dexamethasone didn't increase the likelihood of complete symptom resolution after 24 hours, and although more patients taking the steroid reported feeling completely better after 48 hours, a role for steroids to treat sore throats in primary care is uncertain, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 18, 2017 Category: Science Source Type: news

Dexamethasone Sodium Phosphate Injection (Updated - Resolved)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - April 13, 2017 Category: Drugs & Pharmacology Source Type: news

PVR and Steroid Implants -- A Good Fit? PVR and Steroid Implants -- A Good Fit?
Have dexamethasone implants changed the treatment landscape of proliferative vitreoretinopathy? Dr Sophie Bakri'eyes'the latest research.Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 13, 2017 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news

RVD Plus Transplantation Delayed Progression in Myeloma
Combined treatment with lenalidomide, bortezomib, and dexamethasone plus transplantation significantly delayed progression in patients with multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - April 12, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

High-dose dexamethasone for cardiac surgery saves costs
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 1, 2017 Category: Drugs & Pharmacology Source Type: news

‘VCD-Lite’ Viable Option for Older, Toxicity-Vulnerable Myeloma Patients
Dose-attenuated bortezomib, cyclophosphamide, and dexamethasone (VCD-lite) is a viable treatment option for vulnerable or frail adults with newly diagnosed multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - March 21, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Ozurdex (Dexamethasone Intravitreal Implant) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 20, 2017 Category: Drugs & Pharmacology Source Type: news

Amgen Presents Overall Survival Data From KYPROLIS ® (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop
Late-Breaking Presentation to Show Overall Survival Benefit of KYPROLIS Compared to Velcade® (Bortezomib) in Relapsed or Refractory Multiple Myeloma Patients First-and-Only Head-to-Head Study Comparing Proteasome Inhibitors to Demonstrate Statistically Significant Improved Overall Survival THOUSAND OAKS, Calif., March 3, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive results from a planned overall survival (OS) interim analysis of the Phase 3 head-to-head ENDEAVOR trial. The study met the key secondary endpoint of OS, demonstrating that patients with relapsed or refractory multiple myelom...
Source: Amgen News Release - March 3, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

' DaraLenDex' Combo Best for Relapsed/Refractory Multiple Myeloma'DaraLenDex' Combo Best for Relapsed/Refractory Multiple Myeloma
The combination of daratumumab, lenalidomide and dexamethasone (DaraLenDex) appears to offer the best outcomes in patients with relapsed and/or refractory multiple myeloma (MM), according to a network meta-analysis involving 18 treatment options.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 3, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Phase 3 Head-to-Head Trial Showed KYPROLIS ® (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade® (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients
First-and-Only Head-to-Head Study Comparing Proteasome Inhibitors to Demonstrate Statistically Significant Improved Overall Survival Detailed Results Will be Presented at the 16th International Myeloma Workshop (IMW) in New Delhi THOUSAND OAKS, Calif., Feb. 28, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive results from a planned overall survival (OS) interim analysis of the Phase 3 head-to-head ENDEAVOR trial. The study met the key secondary endpoint of OS, demonstrating that patients with relapsed or refractory multiple myeloma treated with KYPROLIS® (carfilzomib) and dexamethasone (Kd)...
Source: Amgen News Release - February 28, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news